Mercer Global Advisors’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$173K Buy
18,373
+4,525
+33% +$36.2K ﹤0.01% 3468
2026
Q2
$121K Buy
13,848
+1,107
+9% +$8.38K ﹤0.01% 3383
2026
Q1
$93.6K Sell
12,741
-826
-6% -$5.65K ﹤0.01% 3034
2025
Q4
$26.9K Sell
13,567
-3,392
-20% -$7.68K ﹤0.01% 2814
2025
Q3
$41.7K Sell
16,959
-19,865
-54% -$51.2K ﹤0.01% 2597
2025
Q2
$97.2K Buy
+36,824
New +$99K ﹤0.01% 2160
2025
Q1
– Sell
-37,006
Closed -$94.7K – 2205
2024
Q4
$94.7K Buy
37,006
+8,359
+29% +$34.8K ﹤0.01% 2046
2024
Q3
$103K Buy
28,647
+8,743
+44% +$40.5K ﹤0.01% 1876
2024
Q2
$126K Buy
+19,904
New +$131K ﹤0.01% 1854

Other funds holding IBRX

Mercer Global Advisors's IBRX Position: Q3 2026 in Review

Mercer Global Advisors increased its ImmunityBio (IBRX) stake by 33% in Q3 2026, buying an estimated $36.2K and bringing the position to 18,373 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #3468.

Mercer Global Advisors first reported a position in IBRX in Q2 2024 and has held it in 9 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.

  • Mercer Global Advisors held 18,373 shares of ImmunityBio worth $173K as of Q3 2026.
  • Mercer Global Advisors bought 4,525 ImmunityBio shares in Q3 2026, an estimated $36.2K.
  • ImmunityBio made up ﹤0.01% of Mercer Global Advisors's portfolio in Q3 2026, its #3468 holding.
  • Mercer Global Advisors first reported a position in ImmunityBio in Q2 2024 and has held it in 9 quarters since.
  • 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.

Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.